Xilio Therapeutics, Inc. is a clinical stage biotechnology company discovering and developing masked immuno oncology therapies. The company uses a proprietary masking technology that keeps therapeutic molecules inactive until they reach the tumor microenvironment where tumor specific proteases remove the mask and activate the drug. This approach aims to deliver potent anti tumor activity while limiting exposure to healthy tissues and reducing the side effects seen with systemically active immuno oncology agents. Xilio’s platform combines deep expertise in biology and protein engineering with computational design tools to create a range of masked molecules including bispecific antibodies T cell engagers and cytokine based therapies. The company is advancing multiple programs in preclinical and clinical development with the goal of bringing novel treatments to patients with cancer.

Xilio generates revenue primarily through collaboration and licensing agreements with larger pharmaceutical partners. Upfront payments equity investments and milestone payments form the core of its current income streams. In February 2025 the company received a total of fifty two million dollars from AbbVie consisting of a forty two million dollar cash payment and a ten million dollar equity investment. In March 2024 Xilio entered into an agreement with Gilead that provided a thirty million dollar upfront cash payment twenty five million dollars in proceeds from stock purchases and subsequent milestone payments. The company is eligible to receive additional contingent payments from these partners tied to development regulatory and sales milestones as well as tiered royalties on future net product sales. These arrangements allow Xilio to fund its research and development efforts while retaining rights to its platform technology.

Xilio occupies a niche within the broader immuno oncology field by focusing on masked therapies that aim to improve the safety profile of existing immune modulators. The company faces competition from other biotechnology firms exploring similar approaches such as Anaveon Bright Peak Therapeutics Innovent Biologics Medicenna Regeneron Roche and Teva for PD 1 IL 2 bispecifics and from Janux Therapeutics Vir Biotechnology Werewolf Therapeutics Amgen Astellas AstraZeneca and others for T cell engagers targeting PSMA STEAP1 or CLDN18 2. Xilio’s competitive advantage lies in its validated masking platform which enables tumor selective activation a broad applicability across solid tumor types and the ability to engineer molecules with customized half life properties. The intellectual property portfolio including numerous patent families covering the core technology and specific product candidates further supports its market position.

Xilio’s customers are ultimately patients with cancer who will receive its therapeutic candidates once they achieve regulatory approval. In the near term the company works with pharmaceutical partners such as AbbVie and Gilead who provide funding and expertise to advance the programs. These collaborations involve joint research development and potential commercialization activities. The company also engages with clinical trial sites health care providers and investigational sites to enroll patients in its studies. As its product candidates progress the patient population and treating physicians will become the primary end users of the therapies.